Jazz Pharmaceuticals’ Board of Directors has unanimously selected Renee Gala, Jazz’s President and Chief Operating Officer, as President and Chief Executive Officer, effective August 11, 2025.

She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company’s next leader. This appointment reflects a key milestone in the Board’s long-term succession planning process and previously disclosed CEO transition.

About Renee Gala

Gala was promoted to the role of President and COO in October 2023, after having served as Executive Vice President and Chief Financial Officer of the Company since March 2020. She brings more than 30 years of experience across finance, strategy, corporate development and commercialization. In her current role, she oversees the Company’s global business operations, which include commercial, medical, research and development, technical operations and quality, as well as corporate strategy. Gala has played a critical role in driving Jazz’s ongoing transformation, including architecting a business development strategy that has diversified the Company’s portfolio, driven total revenue growth of nearly 90%, built broad capabilities, and established a pipeline that has positioned the Company for value creation and sustainable growth.

“I am honored to step into the CEO role and build upon Jazz’s extraordinary legacy, fueled by exceptional people, a spirit of purpose and an unwavering commitment to patients,” said Gala. “With a market-leading portfolio of medicines, a promising pipeline, a strong financial position and an ongoing focus on corporate development, Jazz has immense potential—and more work to be done to realize it.”

Cozadd will continue to serve as Chairperson of the Board, providing strategic input as the Company continues to execute on its growth strategy.